Search
Hycanthone
go.drugbank.com/drugs/DB14061ExperimentalPotentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE. Hycanthone was approved by the FDA in 1975 but is no longer used.
Cinnarizine
go.drugbank.com/drugs/DB00568ApprovedInvestigationalFirst synthesized by Janssen Pharmaceuticals in 1955, cinnarizine is an anti-histaminic drug mainly used for the control of vestibular disorders and motion sickness. … Cinnarizine is a specific calcium channel blocker that primarily works on the central vestibular system to interfere with the signal transmission between vestibular apparatus of the inner ear and the vomiting
Relugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigational[L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022.[L42150] Relugolix has also been studied in the symptomatic treatment of endometriosis. … It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids,[A225816] and more recently by the United States' FDA in 2020, under the brand name
Satralizumab
go.drugbank.com/drugs/DB15762ApprovedInvestigational[A218546,A218551] Satralizumab is thought to exert its therapeutic benefits by blocking IL-6 receptors and, subsequently, these inflammatory responses. … [A218551] Some of the pro-inflammatory mechanisms involved in NMOSD are thought to be mediated, at least in part, by IL-6, including increased production of anti-aquaporin-4 (AQP4) autoantibodies and increased
Enoximone
go.drugbank.com/drugs/DB04880ApprovedInvestigationalWithdrawnTrials were halted in the U.S., but the drug is used in various countries. … Enoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption.
Tisotumab vedotin
go.drugbank.com/drugs/DB16732ApprovedInvestigationalTisotumab vedotin is the first TF-directed ADC [A238914] that works by binding to TFs expressed on solid tumours. … Tisotumab vedotin targets TF-expressing cells to deliver MMAE to induce direct cytotoxicity and bystander killing of neighboring cells.
Benzhydrocodone
go.drugbank.com/drugs/DB15465ApprovedIt was first approved by the FDA in February 2018 in combination with [acetaminophen] under the trade name Apadaz, marketed by KVK Tech and developed by KemPharm.[L7859,L7862] … [L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse.
Propiverine
go.drugbank.com/drugs/DB12278ApprovedOveractive bladder (OAB) is a chronic condition of the lower urinary tract characterized by urinary urgency, increased frequency of urination, and nocturia (frequent waking during the night to urinate) … OAB has a negative impact on quality of life and may lead to leakage and inconvenient urinary accidents [L2327], [L2328].
Products: MICTONORM UNO 30MG, MICTONORM UNO 45MGErenumab
go.drugbank.com/drugs/DB14039ApprovedInvestigationalAimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specifically developed to prevent migraine by blocking the … Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines
Pegaspargase
go.drugbank.com/drugs/DB00059ApprovedInvestigational[A255912,A255917] In February 1994, pegaspargase was approved by the FDA for the treatment of ALL in patients with hypersensitivity to native forms of L-asparaginase.[A255927] … However, leukemia cells have low levels of this enzyme and depend on exogenous sources. Therefore, the use of pegaspargase results in leukemic cell death.